reports
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
- Wedbush Research
VMW VMWARE INC. CLASS A
ADS ADIDAS AG
ACN ACCENTURE PLC CLASS A
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GME GAMESTOP CORP. CLASS A
FL FOOT LOCKER INC.
FB FACEBOOK INC. CLASS A
DKS DICK'S SPORTING GOODS INC.
AXTI AXT INC.
NFLX NETFLIX INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
HPE HEWLETT PACKARD ENTERPRISE CO.
CELH CELSIUS HOLDINGS INC.
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
NKE NIKE INC. CLASS B
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
NICE NICE LTD
DELL DELL TECHNOLOGIES INC CLASS C
ASO ACADEMY SPORTS AND OUTDOORS
PLTR PALANTIR TECHNOLOGIES
MRVL MARVELL TECHNOLOGY INC
STX SEAGATE TECHNOLOGY HLDGS PLC
GFS GLOBALFOUNDRIES INC
RBRK RUBRIK INC
- Matt Quigley
- Tom Nikic
Moody's Ratings affirms ModivCare's B3 CFR, assigns B2 first lien rati...
Moody's Ratings (Moody's) affirmed ModivCare Inc.'s ("ModivCare") B3 Corporate Family Rating (CFR) and B3-PD Probability of Default Rating (PDR) and assigned B2 ratings to the company's first lien senior secured revolving credit facility due 2028 and new first lien senior secured term loan B due 203...
- Research Team ACF
Regenerative Healthcare - Stem Cells & ALS Thematic 10062024
Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...
NOVN NOVARTIS AG
CG3 CELGENE CORPORATION
QURE UNIQURE NV
MRK MERCK & CO. INC.
JNJ JOHNSON & JOHNSON
GILD GILEAD SCIENCES INC.
CYTK CYTOKINETICS INCORPORATED
BMY BRISTOL-MYERS SQUIBB COMPANY
BIIB BIOGEN INC.
BCLI BRAINSTORM CELL THERAPEUTICS
SAN SANOFI
4523 EISAI CO. LTD.
IONS IONIS PHARMACEUTICALS INC.
WVE WAVE LIFE SCIENCES
PFE PFIZER INC.
ABBV ABBVIE INC.
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
TEVA TEVA PHARMACEUTICAL INDUSTRIES LIMITED
NOVO NOVO NORDISK A/S-B
Nike Inc: 1 director
A director at Nike Inc sold 9,350 shares at 95.100USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
Blueprint Medicines Corp: 1 director
A director at Blueprint Medicines Corp sold 4,000 shares at 105.130USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Chemed Corp: 1 director
A director at Chemed Corp sold 1,500 shares at 544.170USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
- Wedbush Research
- Matt Quigley
- Tom Nikic
Victoria’s Secret & Co. Reports First Quarter 2024 Results
Victoria’s Secret & Co. Reports First Quarter 2024 Results First quarter sales, operating income and EPS at high-end of previously announced preliminary results Provides second quarter guidance and reaffirms full year 2024 outlook Proxy advisory firms recommend in favor of all director candidates, approval of increased capacity under the stock plan, and say-on-pay REYNOLDSBURG, Ohio, June 05, 2024 (GLOBE NEWSWIRE) -- Victoria’s Secret & Co. (“Victoria’s Secret” or the “Company”) (NYSE: VSCO) today reported financial results for the first quarter ended May 4, 2024. Chief Executive Offi...
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
- Wedbush Research
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
HII Names Strategic Leadership to Advance AUKUS Goals in Australia
HII Names Strategic Leadership to Advance AUKUS Goals in Australia CANBERRA, Australia, June 03, 2024 (GLOBE NEWSWIRE) -- HII’s (NYSE: HII) Mission Technologies division announced the appointment of Tim Brown as vice president of operations and Terry Nichols as the managing director for two HII business areas in Australia. Brown and Nichols will work from HII’s Canberra office, and both will report directly to Michael Lempke, president of Mission Technologies’ Nuclear and Environmental Services business group and the leader of HII’s Australia operations working to advance the goals of th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.